spacer
home > ebr > winter 2018 > fight against resistance
PUBLICATIONS
European Biopharmaceutical Review

Fight Against Resistance

Microbial resistance to antibiotics is rising. Keiji Fukuda at the WHO has described antimicrobial resistance (AMR) as a major threat to global public health, stating “Without urgent, coordinated action by many stakeholders, the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill” (1). AMR is a natural and inevitable phenomenon, an outcome of natural selection; bacteria always have evolved to resist threats to their survival and will continue to do so. AMR cannot be completely prevented, but urgent action must be taken to curtail it and minimise its impact on global health.

Excessive and inappropriate use of antibiotics and antimicrobials more widely – combined with inadequate infection control and poor hygiene – are the main factors contributing to the spread of resistance, according to the European Commission’s statement on AMR (2). Decades of over-prescription and off-prescription use, in both humans and animals, have exacerbated the problem, and development of new antibiotics has all but stalled, with far fewer new drugs being licensed in the last couple of decades than in the early and mid-20th century.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Michele Barbour is Chief Executive Officer of Pertinax Pharma. Pertinax technology was developed by her research group at the University of Bristol, UK, where she is Reader in biomaterials and Deputy Head of Bristol Dental School, UK. Michele is the author of over 50 peer-reviewed publications and a leading textbook. She founded Pertinax Pharma in 2015 to commercialise the technology that allows the controlled and sustained release of the antiseptic chlorhexidine.
spacer
Dr Michele Barbour
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine

VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.
More info >>

White Papers

Case Study: Molly™ Auto Injector

SHL Group

The Molly™ Auto Injector is a revolutionary, ultra-compact device, designed for convenience and portability. With the handling process reduced to only 2 simple steps— uncap and inject — Molly™ is incredibly intuitive to use, and quickly became a new benchmark for the auto injector industry. In addition to the many enhanced features that benefit patients, Molly™ was also uniquely designed to offer an alternative business model for customers, one that allowed them to minimize initial investments while maximizing speed-to-market.
More info >>

 
Industry Events

BioPharm America 2018

5-6 September 2018, Hynes Convention Center

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement